Enanta Pharmaceuticals, Inc. ENTA R2K

Healthcare · Biotechnology · United States

https://www.enanta.com

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; EDP-978 for chronic spontaneous urticaria (CSU); Glecaprevir, antiviral protease inhibitors for the treatment of chronic infection with hepatitis C virus or HCV; and EPS-3903 for the treatment of atopic dermatitis. It has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. The company was incorporated in 1995 and is headquartered in Watertown, Massachusetts.

Market & Price

Market Cap

$382.67M

Current Price

$13.16

High / Low (52W)

$16.85 / $5.93

Beta

1.01

Valuation

Stock P/E

Industry PE

23.65

Forward P/E

PEG Ratio

Book Value

$4.01

Price to Book

3.28

P/S

5.53

EV/EBITDA

-7.31

Dividend Yield

Profitability & Returns

ROCE

-32.68%

ROE

-59.00%

ROA

-11.84%

Profit Margin

-89.55%

Op Margin

-69.07%

EPS (Latest Qtr)

$-0.45

EPS (TTM)

$-2.60

Balance Sheet & Liquidity

Debt/Equity

1.60

Quick Ratio

3.69

Current Ratio

3.84

Debt

$186.62M

Total Assets

$280.73M

Current Assets

$204.34M

Working Capital

$155.78M

Ownership

Promoter Holding

4.68%

Chg in Prom Hold

FII / Inst Holding

92.82%

Chg in FII Hold

Financial Snapshot

Enterprise Value

$405.51M

Total Revenue (TTM)

$69.21M

EBITDA

$-55.45M

Free Cash Flow

$7.69M

Operating Cash Flow

$-7.84M

Shares Outstanding

29.08M

Gross Margin

100.00%

Payout Ratio

0.00%

Growth (CAGR)

Revenue 5Y

-8.82%

Profit 5Y

10.91%

Revenue (YoY)

15.00%

Earnings (YoY)

PROS

Profit CAGR of 10.9% over 5 years.
Generates positive free cash flow.
In a confirmed uptrend (50-DMA above 200-DMA).

CONS

Revenue declined at -8.8% CAGR over 5 years.

* The pros and cons are auto-generated from financial metrics.

Price Chart

Robinhood TradingView StockAnalysis

Fundamental Growth

Period: Metric:

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	ENTA Enanta Pharmaceuticals, Inc. R2K	13.16	-	$382.67M	-	-32.68%	-59.00%	-8.82%	10.91%
2	LLY Eli Lilly and Company SPX	1,105.00	39.21	$985.37B	0.63%	38.44%	107.46%	31.69%	48.96%
3	JNJ Johnson & Johnson SPX	225.33	26.11	$542.42B	2.38%	23.13%	26.42%	5.60%	14.32%
4	UNH UnitedHealth Group Incorporated SPX	380.31	28.66	$345.38B	2.32%	9.60%	12.18%	11.35%	-15.69%
5	MRK Merck & Co., Inc. SPX	118.72	33.44	$293.22B	2.86%	20.66%	18.94%	3.12%	7.93%
6	TMO Thermo Fisher Scientific Inc. SPX	492.51	27.11	$183.03B	0.38%	9.17%	13.52%	-0.27%	-1.19%
7	AMGN Amgen Inc. NDXSPX	336.79	23.42	$181.77B	2.99%	18.02%	101.32%	11.77%	5.58%
8	GILD Gilead Sciences, Inc. NDXSPX	134.43	18.29	$166.90B	2.44%	22.92%	43.36%	2.57%	22.83%
9	ISRG Intuitive Surgical, Inc. NDXSPXAI	424.64	51.53	$150.39B	-	15.96%	17.23%	17.39%	29.26%

Quarterly Results

Figures in USD.

Metric	Jun 2015	Sep 2015	Dec 2015	Mar 2016	Jun 2016	Sep 2016	Dec 2016	Mar 2017	Jun 2017	Sep 2017	Dec 2017	Mar 2018	Jun 2018	Sep 2018	Dec 2018	Mar 2019	Jun 2019	Sep 2019	Dec 2019	Mar 2020	Jun 2020	Sep 2020	Dec 2020	Mar 2021	Jun 2021	Dec 2021	Mar 2022	Jun 2022	Dec 2022	Mar 2023	Jun 2023	Dec 2023	Mar 2024	Jun 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Revenue	-	-	-	-	-	-	10.42M	8.96M	7.51M	75.93M	38.11M	44.05M	57.26M	67.20M	69.89M	39.63M	44.37M	51.31M	52.57M	27.62M	18.65M	23.63M	31.74M	20.13M	21.62M	27.65M	18.72M	19.48M	23.59M	17.80M	18.89M	18.00M	17.05M	17.97M	16.96M	14.93M	18.31M	15.12M	18.61M	17.16M
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	39.45M	37.21M	33.51M	29.87M	29.01M
Operating Income	1.70M	-	35.59M	-565.00K	-1.09M	-	-7.05M	-9.51M	-13.13M	-	14.38M	16.86M	22.64M	-	27.86M	-1.30M	3.75M	-	12.87M	-11.88M	-22.85M	-	-12.30M	-29.70M	-33.85M	-30.41M	-33.85M	-32.54M	-30.01M	-39.45M	-36.71M	-34.89M	-32.77M	-24.18M	-23.54M	-24.53M	-18.89M	-18.39M	-11.25M	-11.85M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-21.03M	-15.40M	-15.00M	-7.60M	-8.56M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.71M	1.62M	2.39M	3.08M	3.32M
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-23.95M	-18.23M	-18.67M	-11.91M	-13.08M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-1.30M	29.00K	32.00K	24.00K	7.00K
Net Income	2.42M	5.81M	26.19M	-1.65M	-1.08M	-1.80M	-4.98M	-5.39M	-8.43M	36.51M	11.69M	12.55M	20.29M	27.42M	26.01M	4.14M	7.04M	9.19M	13.44M	-6.00M	-14.27M	-29.34M	-8.33M	-22.05M	-24.02M	-30.11M	-33.59M	-31.70M	-28.99M	-37.66M	-39.06M	-33.41M	-31.16M	-22.66M	-22.29M	-22.64M	-18.25M	-18.70M	-11.94M	-13.09M
Diluted EPS	0.13	0.29	1.37	-0.09	-0.06	-0.09	-0.26	-0.28	-0.44	1.86	0.59	0.61	0.97	1.30	1.25	0.20	0.33	0.44	0.65	-0.30	-0.71	-1.46	-0.41	-1.09	-1.19	-1.48	-1.63	-1.53	-1.39	-1.79	-1.86	-1.58	-1.47	-1.07	-1.05	-1.06	-0.85	-0.87	-0.42	-0.45
R&D Expense	6.25M	-	9.03M	9.14M	10.79M	-	12.53M	13.00M	15.41M	-	17.96M	21.48M	28.49M	-	34.88M	34.16M	34.46M	-	32.78M	32.61M	34.68M	-	36.66M	41.51M	46.99M	48.55M	42.09M	39.09M	40.90M	43.47M	42.99M	36.37M	35.59M	28.74M	27.66M	28.07M	27.21M	-	20.86M	19.44M

Profit & Loss (Annual)

Figures in USD.

Metric	Sep 2011	Sep 2012	Sep 2013	Sep 2014	Sep 2015	Sep 2016	Sep 2017	Sep 2018	Sep 2019	Sep 2020	Sep 2021	Sep 2022	Sep 2023	Sep 2024	Sep 2025
Revenue	-	-	-	-	-	88.27M	102.81M	206.62M	205.20M	122.47M	-	86.16M	79.20M	67.64M	65.32M
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	210.00M	216.41M	189.33M	150.67M
Operating Income	25.30M	21.29M	9.03M	18.98M	124.15M	30.84M	24.61M	88.33M	36.74M	-41.64M	-	-123.84M	-137.21M	-121.69M	-85.35M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-119.22M	-123.48M	-104.51M	-71.28M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	0	5.15M	10.94M	7.68M
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-122.19M	-131.00M	-117.79M	-83.55M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-433.00K	2.82M	-1.74M	-1.66M
Net Income	23.31M	21.40M	9.63M	34.44M	78.99M	21.67M	17.71M	71.96M	46.38M	-36.17M	-	-121.75M	-133.82M	-116.05M	-81.89M
Diluted EPS	1.32	1.13	-0.67	1.80	4.09	1.13	0.91	3.48	2.21	-1.81	-	-5.91	-6.38	-5.48	-3.84
R&D Expense	11.55M	15.12M	16.84M	18.74M	23.19M	40.46M	57.45M	94.86M	142.21M	136.76M	174.11M	164.52M	163.52M	131.48M	106.74M

Compounded Sales Growth

5 Years:	-8.82%
1 Year:	15.00%

Compounded Profit Growth

5 Years:	10.91%
1 Year:	-

Stock Price Performance

1 Year:	+121.92%
6 Months:	-3.66%
3 Months:	-7.97%
1 Month:	-5.12%

Balance Sheet (Annual)

Figures in USD.

Metric	Sep 2010	Sep 2011	Sep 2012	Sep 2013	Sep 2014	Sep 2015	Sep 2016	Sep 2017	Sep 2018	Sep 2019	Sep 2020	Sep 2021	Sep 2022	Sep 2023	Sep 2024	Sep 2025
Total Assets	-	-	52.16M	116.97M	155.41M	246.01M	281.28M	326.64M	414.23M	489.83M	486.13M	-	375.41M	462.27M	376.65M	280.73M
Current Assets	-	-	-	-	-	-	-	-	-	-	-	-	311.71M	422.79M	299.85M	204.34M
Cash & Equivalents	466.00K	6.84M	10.51M	8.86M	30.70M	21.73M	16.58M	65.67M	63.90M	51.23M	87.13M	-	43.99M	85.39M	37.23M	32.30M
Inventory	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Receivables	-	-	-	-	-	-	-	-	-	-	-	-	20.32M	8.61M	6.65M	6.88M
Total Liabilities	-	-	8.23M	6.50M	6.76M	9.86M	11.34M	24.96M	20.55M	27.34M	30.55M	-	54.08M	245.54M	247.84M	216.01M
Current Liabilities	-	-	5.73M	4.53M	4.75M	6.70M	7.89M	20.98M	16.02M	22.61M	24.16M	-	29.83M	62.79M	57.53M	48.55M
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Debt	-	-	-	-	-	-	-	-	-	-	-	-	25.26M	26.51M	55.47M	57.90M
Total Equity	-150.07M	-131.96M	-115.35M	110.47M	148.65M	236.16M	269.94M	301.68M	393.68M	462.49M	455.58M	-	321.33M	216.74M	128.81M	64.72M
Shares Outstanding	-	-	-	-	-	-	-	-	-	-	-	-	20.79M	21.06M	21.19M	21.39M

Cash Flows (Annual)

Figures in USD.

Metric	Sep 2011	Sep 2012	Sep 2013	Sep 2014	Sep 2015	Sep 2016	Sep 2017	Sep 2018	Sep 2019	Sep 2020	Sep 2021	Sep 2022	Sep 2023	Sep 2024	Sep 2025
Operating Cash Flow	24.02M	22.62M	10.65M	-	-	35.81M	52.65M	29.22M	71.42M	7.09M	-	-84.78M	-103.15M	-78.76M	-19.27M
Investing Cash Flow	-17.68M	-18.04M	-69.22M	-	-	-43.66M	-4.57M	-35.40M	-86.66M	19.83M	-	54.90M	-53.58M	58.23M	40.35M
Financing Cash Flow	34.00K	-909.00K	56.91M	-	-	2.71M	1.02M	4.41M	2.57M	8.98M	-	20.03M	198.13M	-27.63M	-26.62M
Capital Expenditure	-445.00K	-252.00K	-606.00K	-1.03M	-2.34M	-4.74M	-2.51M	-2.98M	-5.42M	-1.45M	-	-2.12M	-9.06M	-17.95M	-12.90M
Free Cash Flow	23.57M	22.37M	10.05M	-	-	31.07M	50.15M	26.24M	66.00M	5.64M	-	-86.91M	-112.21M	-96.71M	-32.17M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-	-	-9.85M	41.39M	-48.16M	-5.54M

Ratios (Annual)

Figures in %.

Metric	Sep 2011	Sep 2012	Sep 2013	Sep 2014	Sep 2015	Sep 2016	Sep 2017	Sep 2018	Sep 2019	Sep 2020	Sep 2021	Sep 2022	Sep 2023	Sep 2024	Sep 2025
Gross Margin %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Margin %	-	-	-	-	-	34.9%	23.9%	42.7%	17.9%	-34.0%	-	-143.7%	-173.2%	-179.9%	-130.7%
Net Margin %	-	-	-	-	-	24.5%	17.2%	34.8%	22.6%	-29.5%	-	-141.3%	-169.0%	-171.6%	-125.4%
ROE %	-17.7%	-18.6%	8.7%	23.2%	33.4%	8.0%	5.9%	18.3%	10.0%	-7.9%	-	-37.9%	-61.7%	-90.1%	-126.5%
ROCE %	-	45.9%	8.0%	12.6%	51.9%	11.3%	8.1%	22.2%	7.9%	-9.0%	-	-35.8%	-34.3%	-38.1%	-36.8%

Shareholding Pattern

Insiders

4.68%

Institutions

92.82%

Public Float

97.38%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Janus Henderson Group PLC	13.01%	3.78M	$49.80M
2	Blackrock Inc.	10.67%	3.10M	$40.85M
3	Farallon Capital Management LLC	9.88%	2.87M	$37.79M
4	Krensavage Asset Management, LLC	9.86%	2.87M	$37.72M
5	Deep Track Capital, Lp	6.73%	1.96M	$25.75M
6	Vanguard Capital Management LLC	4.05%	1.18M	$15.50M
7	Vanguard Portfolio Management LLC	3.26%	948.90K	$12.49M
8	Spruce Street Capital LP	3.21%	932.60K	$12.27M
9	Acadian Asset Management. LLC	3.03%	880.02K	$11.58M
10	Millennium Management Llc	3.03%	882.10K	$11.61M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for ENTA

No recent headlines available.

ENTA · Healthcare